The Rules of Investing Life changing technology meets a structural growth industry
5 snips
Jul 18, 2025 Jacob Celermajer, founder of Cordis Asset Management and creator of Australia’s only pure play medtech fund, dives into the transformative world of medical technology. He discusses how innovation in healthcare rivals that of tech giants. Key topics include the promising investment landscape shaped by an aging population, the crucial role of medical advisory panels, and revolutionary treatments like mechanical thrombectomy that enhance patient outcomes. Celermajer offers valuable investing insights while navigating the unique challenges of the medtech sector.
AI Snips
Chapters
Transcript
Episode notes
MedTech's Strong Long-Term Outlook
- MedTech is predicted to outperform healthcare and the broader market long-term due to three pillars: aging population, medical tech revolution, and strong company moats.
- It has returned over 13.5% per annum for 20 years and similar growth is expected in the future.
Founders' Insight on MedTech Cycle
- MedTech fund founders included a cardiothoracic surgeon and a medical engineer who saw patients living longer due to implants like pacemakers and stents.
- These patients then return for more medical technology, creating a 'virtuous cycle' of adoption and longevity.
Focus Narrow for MedTech Investing
- Narrow the investable universe using medical expertise to about 30-40 companies out of about 1,000 medtech firms.
- Build a concentrated, high-conviction, low-turnover portfolio grounded in clinical knowledge.